Search results for " severity"

showing 10 items of 284 documents

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

2020

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COV…

Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Index
researchProduct

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

2017

Abstract Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyConcordanceSocio-culturalePractice PatternsSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Retrospective StudieSurveys and QuestionnairesSeverity of illnessHealth caremedicineSurveys and QuestionnaireHumansPharmacology (medical)030212 general & internal medicinePractice Patterns Physicians'Adult; Aged; Asthma; Female; Humans; Italy; Male; Middle Aged; Practice Patterns Physicians'; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of Life; SpecializationAsthmaAgedRetrospective StudiesModalitiesPhysicians'business.industryBiochemistry (medical)Retrospective cohort studyMiddle Agedmedicine.diseaseAsthmaPulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)030228 respiratory systemItalyTest scoreFamily medicinePhysical therapyQuality of LifeFemalebusinessHumanSpecializationPulmonary pharmacologytherapeutics
researchProduct

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

2020

Tiotropium Respimat is an efficacious add-on to maintenance treatment in patients with symptomatic asthma. Currently, the Global Initiative for Asthma (GINA) strategy recommends tiotropium for patients at Steps 4–5. To assess the clinical benefits of tiotropium Respimat across asthma severities, GINA Steps 2–5, a post hoc analysis of five double-blind trials (12–48-weeks; patients aged 18–75 years) investigated the effect of tiotropium Respimat, 5 μg or 2.5 μg, versus placebo, on peak forced expiratory volume in 1 s (FEV1) within 3 h post-dose (FEV1(0–3h)) response, and Asthma Control Questionnaire-7 (ACQ-7) responder rate. GINA step grouping was based on patients’ background treatment regi…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyRespimatAdolescentINHALED CORTICOSTEROIDSPlaceboSALMETEROLDouble-Blind MethodADD-ONStatistical significanceInternal medicineAsthma controlPost-hoc analysisAdministration InhalationmedicineHumansPharmacology (medical)Tiotropium BromideCOMBINATIONDisease severityLungAsthmaAgedbusiness.industryTiotropiumBiochemistry (medical)IMPROVES LUNG-FUNCTIONOdds ratioMiddle Agedmedicine.diseaseGINAConfidence intervalLung functionAsthmarespiratory tract diseasesBronchodilator AgentsTreatment OutcomeSAFETYFemaleSalmeterolbusinessmedicine.drugSYMPTOMATIC ASTHMAPulmonary pharmacologytherapeutics
researchProduct

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

2019

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The severity grading systems proposed by the Global initiative for Chronic Obstructive Lung Disease (GOLD) have changed over time. The aim of the study was to evaluate if the different GOLD classifications can capture the complexity of the disease by investigating the distribution of lung function and clinical parameters across the GOLD classification systems. This was an observational, retrospective, multicentre study. COPD patients were stratified according to the GOLD severity grading proposed in the 2007, and to the ABCD assessment tool present in the 2011, and 2017 versions of the initiative. Data from body plethy…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyphenotypeCopd patientsSettore MED/10 - Malattie dell'Apparato RespiratorioVital CapacitySocio-culturalePulmonary diseaseSeverity gradingDiseaseGOLD documentairflow obstructionurologic and male genital diseasesSeverity of Illness IndexPulmonary Disease03 medical and health sciencesLeukocyte CountPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineForced Expiratory VolumemedicineCOPDHumanseosinophil030212 general & internal medicineAgedRetrospective StudiesCOPDbusiness.industryairflow obstruction COPD eosinophil GOLD document phenotypeMiddle Agedmedicine.diseaseObstructive lung diseaserespiratory tract diseasesEosinophils030228 respiratory systemItalyairflow obstruction; COPD; eosinophil; GOLD document; phenotype; Aged; Eosinophils; Female; Forced Expiratory Volume; Humans; Inspiratory Capacity; Italy; Leukocyte Count; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Retrospective Studies; Risk Factors; Severity of Illness Index; Vital CapacityObservational studyFemalesense organsbusinessCOPD; GOLD document; airflow obstruction; eosinophil; phenotypeInspiratory CapacityCOPD
researchProduct

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease

2020

<b><i>Background:</i></b> Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). <b><i>Objectives:</i></b> The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). <b><i>Methods:</i></b> This post hoc analysis of the SAT study included all enrolled …

Pulmonary and Respiratory MedicineMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic ObstructiveHealth BehaviorClinical InvestigationsPulmonary diseaseSocio-culturaleDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Indexchronic obstructive pulmonary diseaseTreatment satisfactionIllness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDiagnostic Self EvaluationInternal medicineSurveys and QuestionnairesPost-hoc analysismedicineSettore MED/10HumansAdherence awareness chronic obstructive pulmonary disease patient-reported outcomesIn patientawarenessPatient Reported Outcome MeasuresAgedCOPDPracticebusiness.industryHealth KnowledgeSelf-Managementmedicine.diseaseSymptom Flare UpAdherence; Awareness; Chronic obstructive pulmonary disease; Patient-reported outcomes; Aged; Female; Health Knowledge Attitudes Practice; Humans; Italy; Male; Patient Reported Outcome Measures; Patient Satisfaction; Severity of Illness Index; Surveys and Questionnaires; Symptom Flare Up; Diagnostic Self Evaluation; Health Behavior; Pulmonary Disease Chronic Obstructive; Self-Management; Treatment Adherence and ComplianceTreatment Adherence and ComplianceItalyPatient SatisfactionAdherencepatient-reported outcomesAttitudesCopd assessment testFemalebusiness
researchProduct

Serum Surfactant Protein D as a Marker of Asthma Severity

2016

Pulmonary and Respiratory MedicinePulmonary Surfactant-Associated Protein Abusiness.industryAsthma severitySurfactant protein DBiomarkerSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseasePulmonary Surfactant-Associated Protein DCritical Care and Intensive Care MedicineAsthma03 medical and health sciences0302 clinical medicine030228 respiratory systemImmunologyMedicineHumans030212 general & internal medicinePulmonary Surfactant-Associated Protein DbusinessCardiology and Cardiovascular MedicineBiomarkersAsthmaPulmonary Surfactant-Associated Protein AHuman
researchProduct

484 Depression Reduces Chance for Clinical Improvement in Heart Transplant Candidates Independent of Disease Severity, Physical Activity and Eating H…

2011

Pulmonary and Respiratory MedicineTransplantationmedicine.medical_specialtyDisease severitybusiness.industryPhysical activityPhysical therapyMedicineSurgeryCardiology and Cardiovascular MedicinebusinessEating habitsDepression (differential diagnoses)The Journal of Heart and Lung Transplantation
researchProduct

Circulating CD34+ cells are decreased in chronic obstructive pulmonary disease.

2006

Pulmonary and Respiratory Medicineaged; antigens; biological markers; blood; blood/immunology; cd34; chronic obstructive; humans; pulmonary disease; severity of illness indexchronic obstructivebusiness.industryCd34 cellsPulmonary diseaseAntigens CD34cd34Severity of Illness IndexPulmonary Disease Chronic ObstructiveText miningantigensbloodImmunologyMedicineHumansblood/immunologybusinessbiological markersBiomarkerspulmonary diseaseAgedProceedings of the American Thoracic Society
researchProduct

Eligibility for treatment with omalizumab in Italy and Germany.

2013

Summary Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Europe, patients must fulfil a number of additional criteria to become eligible for omalizumab therapy, creating a challenge for epidemiology studies to quantify the potential patient pool. Thus, and in the absence of robust data, the number of omalizumab-eligible patients has remained unclear. To assess eligible patient numbers, a chart-audit design approach was employed to measure epidemiology variables based on patient-level data. 770 patient charts were reviewed in designated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs) and respiratory specialists (R…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsReferralEpidemiologySevere asthmaAllergic asthmaEligibility DeterminationOmalizumabPrimary careOmalizumabAntibodies Monoclonal HumanizedSeverity of Illness IndexAntibodiesSampling StudiesDose-Response RelationshipProduct LabelGermanyEpidemiologyMonoclonalmedicinePrevalenceHumansNational levelAnti-Asthmatic AgentsHumanizedAnti-immunoglobulin EEligibilityDose-Response Relationship Drugbusiness.industryPatient SelectionAllergic asthmaImmunoglobulin EAsthmaAntibodies Anti-IdiotypicAnti-IdiotypicTreatment OutcomeItalyQuality of LifeBiological MarkersDrugbusinessBiomarkersmedicine.drugAllergic asthma; Anti-immunoglobulin E; Eligibility; Epidemiology; Anti-Asthmatic Agents; Antibodies Anti-Idiotypic; Antibodies Monoclonal Humanized; Asthma; Biological Markers; Dose-Response Relationship Drug; Eligibility Determination; Germany; Humans; Immunoglobulin E; Italy; Patient Selection; Prevalence; Quality of Life; Sampling Studies; Severity of Illness Index; Treatment OutcomeRespiratory medicine
researchProduct

Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience

2015

Maurizio Vignola was a superb and innovative researcher, who wrote seminal papers on the biology of airway epithelium in asthma. Inflammation and remodelling were the main topics of his research, mostly conducted in biopsy specimens from patients with asthma of variable severity, encompassing the entire spectrum of the disease from mild to severe asthma. His observations contributed to define the biology of asthma as we know it today, and opened the way to the personalised treatment of asthma. His group has successfully continued to investigate the biology and clinical aspects of bronchial asthma, with major interest in the clinical use of biomarkers to monitor disease activity, and in the …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVariable severityAsthma phenotypesSevere asthmaDrug ResistanceMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAdrenal Cortex HormoneDisease activityGlucocorticoidAdrenal Cortex Hormonesimmune system diseasesmedicineHumansIntensive care medicineGlucocorticoidsAsthmalcsh:RC705-779Inflammationbusiness.industrylcsh:Diseases of the respiratory systemBiomarkermedicine.diseaseAsthmarespiratory tract diseasesPhysical therapyAirway RemodelingTreatment strategybusinessBiomarkersHumanEuropean Respiratory Review
researchProduct